+1 (704) 266-3234

Global Lifestyle Drugs Market 2017-2021

Published on: Feb 2017 | From USD $3500 | Published By: INFINITI RESEARCH | Number Of Pages: 91

About Lifestyle Drugs Market
Lifestyle disease is associated with the way an individual or group of people live. Some of the lifestyle diseases include depression, sexual dysfunction, anti-aging, baldness, and obesity.

Technavio’s analysts forecast the global lifestyle drugs market to grow at a CAGR of 2.87% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global lifestyle drugs market for 2017-2021. To calculate the market size, the report considers sales of lifestyle drugs in the market.

The market is divided into the following segments based on geography:
• Americas

Technavio's report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Allergan
• Eli Lilly
• Pfizer

Other prominent vendors
• Acerus Pharmaceuticals
• Alkermes
• Amorepacific
• AndroScience
• Anterios
• AstraZeneca
• Avanir Pharmaceuticals
• Avolynt
• Celtaxsys
• Cerecor
• Corcept Therapeutics
• Cosmo Pharmaceuticals
• CTC Bio
• Dermira
• Dong-A ST
• Euthymics Bioscience
• Foamix
• Follicum
• Forendo Pharma
• Futura Medical Developments
• Galderma
• Hanmi Pharmaceutical
• Incyte
• Intrepid Therapeutics
• Ion Channel Innovations
• iX Biopharma
• Johnson & Johnson
• Legacy Healthcare
• LEO Pharma
• H. Lundbeck
• Luye America Pharmaceuticals
• Merck
• Minerva Neurosciences
• MSI Methylation Sciences
• Neuralstem
• Novan
• Novartis
• Novo-Nordisk
• Palatin Technologies
• Paratek Pharmaceuticals
• Photocure
• Revance Therapeutics
• Rhythm Pharmaceuticals
• S1 Biopharma
• Sage Therapeutics
• Samumed
• Sanofi
• Sigma-Tau Pharmaceuticals
• Strategic Science & Technologies
• Sumitomo Dainippon Pharma
• Takeda
• TetraLogic Pharmaceuticals
• TherapeuticsMD
• Valeant Pharmaceuticals
• VistaGen Therapeutics
• XBiotech
• Yuhan
• Zafgen

Market driver
• Lifestyle changes
• For a full, detailed list, view our report

Market challenge
• Patent expiries
• For a full, detailed list, view our report

Market trend
• Increase in M&A
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: An overview of lifestyle diseases

PART 06: Market landscape

Market overview
Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation  by therapy area

Dermatology (acne, anti-aging, and baldness)
Sexual dysfunction

PART 09: Geographical segmentation

Lifestyle drugs market in Americas
Lifestyle drugs market in EMEA
Lifestyle drugs market in APAC

PART 10: Market drivers

Lifestyle changes
Development of novel therapeutics
Increasing demand from older population

PART 11: Impact of drivers

PART 12: Market challenges

Patent expiries
Side effects coupled with product recalls
Presence of alternative therapies and treatments

PART 13: Impact of drivers and challenges

PART 14: Market trends

Increase in M&A
Growing focus on development of drugs for new indications
Emerging lifestyle diseases

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

Eli Lilly
Other prominent vendors

PART 17: Appendix

List of abbreviation

PART 18: Explore Technavio
List of Exhibits

Exhibit 01: Global lifestyle drugs market snapshot

Exhibit 02: Global lifestyle drugs market 2016-2021 ($ billions)

Exhibit 03: Opportunity analysis in global lifestyle drugs market

Exhibit 04: Five forces analysis

Exhibit 05: Pipeline analysis of vendors in Phase III

Exhibit 06: Key pipeline drugs for depression 2016

Exhibit 07: Key pipeline drugs for dermatology (anti-aging, baldness, and acne) 2016

Exhibit 08: Key pipeline drugs for sexual dysfunction 2016

Exhibit 09: Key pipeline drugs for obesity

Exhibit 10: Global depression drugs market 2016-2021 ($ billions)

Exhibit 11: Global dermatology lifestyle drugs market 2016-2021 ($ billions)

Exhibit 12: Global sexual dysfunction drugs market 2016-2021 ($ billions)

Exhibit 13: Global obesity drugs market 2016-2021 ($ billions)

Exhibit 14: Segmentation of global lifestyle drugs market by geography 2016 and 2021

Exhibit 15: Global lifestyle drugs market revenue by geography 2016-2021 ($ billions)

Exhibit 16: Market scenario in Americas

Exhibit 17: Lifestyle drugs market in Americas 2016-2021 ($ billions)

Exhibit 18: Market scenario in EMEA

Exhibit 19: Lifestyle drugs market in EMEA 2016-2021 ($ billions)

Exhibit 20: Market scenario in APAC

Exhibit 21: Lifestyle drugs market in APAC 2016-2021 ($ billions)

Exhibit 22: Impact of drivers

Exhibit 23: Impact of drivers and challenges

Exhibit 24: Competitive structure analysis of global lifestyle drugs market 2016

Exhibit 25: Competitive analysis of global lifestyle drugs market

Exhibit 26: Market penetration of various lifestyle drug manufacturers worldwide 2016

Exhibit 27: Strategic success factors of companies in global lifestyle drugs market

Exhibit 28: Allergan: Key highlights

Exhibit 29: Allergan: Strength assessment

Exhibit 30: Allergan: Strategy assessment

Exhibit 31: Allergan: Opportunity assessment

Exhibit 32: BMS: Strength assessment

Exhibit 33: BMS: Strategy assessment

Exhibit 34: BMS: Opportunity assessment

Exhibit 35: BMS: YoY and growth rate of Abilify 2013-2015 ($ billions)

Exhibit 36: Eli Lilly: Key highlights

Exhibit 37: Eli Lilly: Strength assessment

Exhibit 38: Eli Lilly: Strategy assessment

Exhibit 39: Eli Lilly: Opportunity assessment

Exhibit 40: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions)

Exhibit 41: Eli Lilly: YoY and growth rate of Zyprexa 2013-2015 ($ millions)

Exhibit 42: Eli Lilly: YoY and growth rate of Strattera 2013-2015 ($ millions)

Exhibit 43: Eli Lilly: YoY and growth rate of Cialis 2013-2015 ($ millions)

Exhibit 44: Pfizer: Key highlights

Exhibit 45: Pfizer: Strength assessment

Exhibit 46: Pfizer: Strategy assessment

Exhibit 47: Pfizer: Opportunity assessment

Exhibit 48: Pfizer: YoY and growth rate of Pristiq 2013-2015 ($ millions)

Exhibit 49: Pfizer: YoY and growth rate of Zoloft 2013-2015 ($ millions)

Exhibit 50: Pfizer: YoY and growth rate of Effexor 2013-2015 ($ millions)

Exhibit 51: Pfizer: YoY and growth rate of Viagra 2013-2015 ($ millions)

Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

The market engineered data is verified and validated by a number of experts, both in-house and external.

After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3500
USD $4500
USD $5000

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.